Accession Number: | 0001209191-21-069349 |
Date: | 2021-12-09 |
Issuer: | AEGLEA BIOTHERAPEUTICS, INC. (AGLE) |
Original Submission Date: |
ALSPAUGH JONATHAN
C/O AEGLEA BIOTHERAPEUTICS, INC.
805 LAS CIMAS PARKWAY, SUITE 100
AUSTIN, TX 78746
Title of Security | Transaction Date | 2a. Deemed Execution Date | Transaction Code | Shares | Acquired or Disposed | Price per share | 5. Amount of Securities Beneficially Owned Following Reported Transaction | 6. Ownership Form Direct or Indirect | Nature of Indirect Ownership |
---|---|---|---|---|---|---|---|---|---|
COMMON STOCK | 2021-12-09 | P | 50,000 | a | $3.72 | 90,372 | direct |
Title of Derivative Security | Conversion or Exercise Price of Derivative Security | Transaction Date | Deemed Execution Date | Transaction Code | Number of Derivative Securities Acquired (A) or Disposed of (D) | Date Exercisable | Expiration Date | Title and Amount of Securities Underlying Derivative Security | Price of Derivative Security | Number of derivative Securities Beneficially Owned Following Reported Transaction(s) | Ownership Form: Direct (D) or Indirect (I) | Nature of Indirect Beneficial Ownership |
---|
ID | footnote |
---|---|
f1 | the reported price in column 4 is a weighted average price. these shares were purchased in multiple transactions at prices ranging from $3.64 to $3.94 per share, inclusive. the reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the securities and exchange commission, upon written request, full information regarding the number of shares purchased at each separate price within the range set forth herein. |